GU Cancers 2024 | Where do ADCs fit in the treatment landscape of urothelial carcinoma?

Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, provides an overview of the emerging role of antibody-drug conjugates (ADCs) in the management of urothelial carcinoma. Whilst enfortumab vedotin with pembrolizumab has been approved in Europe in pre-treated patients based on data from the EV-302 trial (NCT04223856), some centers have been administering this novel treatment strategy in the first-line setting. Whilst patient reimbursement is still occurring in these cases, more research is needed to elucidate the best course of action after treatment with enfortumab vedotin with pembrolizumab. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.